Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$33.37 +3.4%	$34.35	$21.62 ▼ $39.54	$6.13B	1.15	2.44 million shs	2.62 million shs
LNTH Lantheus	$75.52 +1.8%	$92.56	$73.11 ▼ $126.89	$5.22B	0.23	990,521 shs	912,040 shs
ROIV Roivant Sciences	$11.30 +6.4%	$10.53	$8.73 ▼ $13.06	$8.06B	1.23	5.57 million shs	8.43 million shs
RXRX Recursion Pharmaceuticals	$4.45 +1.4%	$4.95	$3.79 ▼ $12.36	$1.81B	0.99	13.61 million shs	21.62 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+3.44%	+1.21%	-8.37%	-4.38%	+20.86%
LNTH Lantheus	+1.81%	+1.03%	-27.36%	-19.51%	-5.33%
ROIV Roivant Sciences	+6.40%	+3.29%	+0.09%	+5.21%	+5.31%
RXRX Recursion Pharmaceuticals	+1.37%	+7.49%	-22.20%	-40.75%	-48.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.532 of 5 stars	4.5	1.0	3.9	3.2	3.3	0.6
LNTH Lantheus	4.3358 of 5 stars	3.5	1.0	4.2	2.7	2.5	1.9
ROIV Roivant Sciences	2.2667 of 5 stars	3.5	3.0	0.0	1.9	2.5	0.0
RXRX Recursion Pharmaceuticals	1.7294 of 5 stars	3.2	1.0	0.0	1.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$57.09	71.08% Upside
LNTH Lantheus	3.00	Buy	$132.67	75.67% Upside
ROIV Roivant Sciences	3.00	Buy	$17.50	54.87% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.60	70.79% Upside

Current Analyst Ratings Breakdown

Latest RXRX, ROIV, LNTH, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/8/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $117.00
5/6/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
4/30/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$46.00 ➝ $63.00
4/30/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $55.00
4/30/2025	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $72.00
4/21/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/15/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$49.00 ➝ $53.00
4/10/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$10.00 ➝ $8.00
4/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/31/2025	BBIO BridgeBio Pharma	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$127.42M	49.73	N/A	N/A	($7.71) per share	-4.33
LNTH Lantheus	$1.54B	3.40	$6.30 per share	11.98	$11.91 per share	6.34
ROIV Roivant Sciences	$122.59M	65.78	N/A	N/A	$7.76 per share	1.46
RXRX Recursion Pharmaceuticals	$59.82M	30.24	N/A	N/A	$1.98 per share	2.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-241.44%	N/A	-75.69%	8/7/2025 (Estimated)
LNTH Lantheus	$326.66M	$3.52	12.57	11.97	N/A	28.57%	44.29%	23.52%	7/30/2025 (Estimated)
ROIV Roivant Sciences	$4.35B	-$0.15	N/A	N/A	N/A	-119.54%	-14.05%	-12.81%	8/6/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$328.07M	-$1.77	N/A	N/A	N/A	-579.52%	-76.56%	-55.68%	8/14/2025 (Estimated)

Latest RXRX, ROIV, LNTH, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million
2/28/2025	Q4 2024	RXRX Recursion Pharmaceuticals	-$0.36	-$0.53	-$0.17	-$0.53	$19.04 million	$4.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.67	4.67
LNTH Lantheus	N/A	1.65	1.56
ROIV Roivant Sciences	N/A	37.91	37.91
RXRX Recursion Pharmaceuticals	0.04	4.35	4.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
LNTH Lantheus	99.06%
ROIV Roivant Sciences	64.76%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
LNTH Lantheus	2.00%
ROIV Roivant Sciences	7.90%
RXRX Recursion Pharmaceuticals	15.75%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	143.29 million	Optionable
LNTH Lantheus	700	69.19 million	68.48 million	Optionable
ROIV Roivant Sciences	860	713.55 million	657.18 million	Optionable
RXRX Recursion Pharmaceuticals	400	406.50 million	329.18 million	Optionable

RXRX, ROIV, LNTH, and BBIO Headlines

Recent News About These Companies

Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) and Genetic Technologies (NASDAQ:GENE)

May 30 at 1:45 AM | americanbankingnews.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 8.2% - Here's Why

May 29 at 3:25 PM | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Here's Why

May 29 at 11:42 AM | marketbeat.com

70,802 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Bought by Man Group plc

May 28 at 3:51 AM | marketbeat.com

RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?

May 27 at 11:01 AM | zacks.com

3 Monster Stocks to Hold for the Next 10 Years

May 26, 2025 | fool.com

Two Sigma Investments LP Grows Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 26, 2025 | marketbeat.com

Deutsche Bank AG Raises Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 26, 2025 | marketbeat.com

Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Increased Net Loss Despite Rising Sales

May 24, 2025 | finance.yahoo.com

These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio (RXRX)

May 22, 2025 | marketbeat.com

Rafferty Asset Management LLC Cuts Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 21, 2025 | marketbeat.com

Raiffeisen Bank International AG Buys New Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 19, 2025 | marketbeat.com

Lazard Asset Management LLC Has $3.76 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 19, 2025 | marketbeat.com

Softbank Group CORP. Invests $99.15 Million in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 18, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by Northern Trust Corp

May 17, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (RXRX) Nosedives 36.55% As AI Drug Discovery Dreams Stall

May 15, 2025 | insidermonkey.com

Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock

May 15, 2025 | zacks.com

Recursion Pharmaceuticals: High-Risk Play Getting Riskier By The Quarter

May 14, 2025 | seekingalpha.com

Recursion Pharmaceuticals, Inc. (RXRX): Among the Best Artificial Intelligence Stocks Under $50 to Buy Now

May 14, 2025 | msn.com

Laurion Capital Management LP Invests $16.61 Million in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 14, 2025 | marketbeat.com

Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?

May 12, 2025 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
By Sam Quirke | May 14, 2025
View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore

RXRX, ROIV, LNTH, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$33.37 +1.11 (+3.44%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$33.31 -0.06 (-0.18%)

As of 05/29/2025 07:32 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Lantheus NASDAQ:LNTH

$75.52 +1.34 (+1.81%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$76.00 +0.48 (+0.64%)

As of 05/29/2025 07:15 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$11.30 +0.68 (+6.40%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$11.25 -0.05 (-0.48%)

As of 05/29/2025 07:57 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Recursion Pharmaceuticals NASDAQ:RXRX

$4.45 +0.06 (+1.37%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$4.38 -0.08 (-1.69%)

As of 05/29/2025 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time